



11-21-05

ZPW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/657383
		Filing Date	September 8, 2003
		First Named Inventor	Yan Chang
		Art Unit	1623
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	8	Attorney Docket Number	GLYO-P03-002


ENCLOSURES (Check all that apply)			
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC	
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	PTO/SB/08	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	Copy of references BF-BQ and CQ3-CA4	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	Return Receipt Postcard	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	ROPES & GRAY LLP		
Signature			
Printed name	Erika Takeuchi		
Date	November 18, 2005	Reg. No.	55,661

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 669630991 US in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 18, 2005

Signature:

(Linda Blake)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 669630991 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 18, 2005

Signature: Linda Blake

(Linda Blake)

Docket No.: GLYO-P03-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Chang et al.

Confirmation No.: 9375

Application No.: 10/657383

Art Unit: 1623

Filed: September 8, 2003

Examiner: Not Yet Assigned

For: **METHOD FOR ENHANCING THE
EFFECTIVENESS OF CANCER
THERAPIES**

November 18, 2005

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information


as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. GLYO-P03-002. A duplicate copy of this paper is enclosed.

Dated: November 18, 2005

Respectfully submitted,

By 

Erika Takeuchi

Registration No.: 55,661

ROPES & GRAY LLP


1251 Avenue of the Americas

New York, New York 10020-1104

(212) 596-9479

(212) 596-9090 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/657383
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	1623
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	GLYO-P03-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AQ	US-5,639,737	06/17/97	Rubin	
	AR	US-6,642,205	11/04/03	Klyosov et al.	
	AS	US-6,645,946	11/11/03	Kkyosov et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BF	WO 02/076474	10-03-2002	Pro-Pharmaceuticals, Inc.		
	BG	WO 02/26262	04-04-2002	Pro-Pharmaceuticals, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CQ3	FRANKEL et al. "Synthetic glycoamine analogs synergies with taxol and cisplatin in inducing programmed cell death in ovarian cancer cells", Proc Am Assoc Can Res (1997) 88 th Ann Meeting, abstr. #627		
	CR3	FUJIMOTO et al., "Clinical Outcome of Postoperative Adjuvant Immunochemotherapy with Sizofiran for Patients with Resectable Gastric Cancer: a Randomised Controlled Study", Eur J Cancer (1991) 27(9), pp. 1114-1118		
	CS3	GLINSKY et al., "Inhibition of Human Breast Cancer Metastasis in Nude Mice by Synthetic Glycoamines", Cancer Research (1996) 56, pp. 5319-5324.		
	CT3	GLINSKY et al., "Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs", Clin. Exp. Metastasis (1996) 14, pp. 253-267.		
	CU3	GLINSKY, G.V., "Anti-adhesion cancer therapy", Cancer and Metastasis Reviews (1998) 17, pp. 177-185.		
	CV3	GREEN et al., "Adhesion-dependent multicellular drug resistance", Anti-Cancer Drug Design (1999) 14, pp. 153-168.		
	CW3	RAZ, A. et al., "Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis", Cancer and Metastasis Reviews (1987) 6, pp. 433-452.		
	CX3	RENARD et al., "Structure of the repeating units in the rhamnogalacturonic backbone of apple, beet and citrus pectins", Carbohydrate Research (1995) 275, pp. 155-165.		
	CY3	ROS et al., "Extraction, characterisation, and enzymatic degradation of lemon peel pectins", Carbohydrate Research (1996) 282, pp. 271-284.		
	CZ3	ROUND et al., "Investigating the nature of branching in pectin by atomic force microscopy and carbohydrate analysis", Carbohydrate Research (2001) 331, pp. 337-342.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/657383
				Filing Date	September 8, 2003
				First Named Inventor	Yan Chang
				Art Unit	1623
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	GLYO-P03-002

CA4	ZHAN et al., "Scarcity or complete lack of single rhamnose residues interspersed within the homogalacturonan regions of citrus pectin", Carbohydrate Research (1998) 308, pp. 373-380
-----	---

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Application No. (if known): 10/657383

Attorney Docket No.: GLYO-P03-002

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 669630991 US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on November 18, 2005
Date

Linda Blake

Signature

Linda Blake

Typed or printed name of person signing Certificate

Registration Number, if applicable

212-596-9000
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)
Fourth Supplemental Information Disclosure Statement (in duplicate)
(Total: 4 pages)
PTO SB/08 (2 pages) (16 references)
Copy of references BF-BG and CQ3-CA4
Return Receipt Postcard
This Certificate of Express Mailing under 37 CFR 1.10